What research abstracts presented at this year’s American Society of Clinical Oncology annual meeting will have the biggest potential impact on clinical practice? Cleveland Clinic Cancer Center physicians make their picks.
The phase 3 KEYNOTE-630 trial has begun enrolling patients with high-risk, locally advanced cutaneous squamous cell carcinoma (cSCC) to evaluate the curative potential of PD-1 inhibitor pembrolizumab.
Pembrolizumab plus axitinib is another effective option for treating renal cell carcinoma, indicates the KEYNOTE-426 study.
In high-risk resected oral cavity squamous cell carcinoma, median disease-free survival doubles when patients receive 200 mg/m2 or more of cisplatin along with radiation therapy, shows one study.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
See these presentations by Cleveland Clinic Cancer Center staff at ASCO 2019.